Nora D. Volkow, M.D. Director National Institute on Drug Abuse National Institutes of Health Nora D. Volkow, M.D. Director National Institute on Drug Abuse.

Slides:



Advertisements
Similar presentations
The Science of Addiction: Implications for Policy Wilson M
Advertisements

Long Term effects of drugs on the brain
The Addicted Synapse Katie Malanson.
Chestnut Health Systems, Normal, IL
Bringing the Full Power of Science to Bear on Drug Abuse & Addiction Drug Abuse & Addiction.
Addiction: Transition from Molecular to Behavioral Understanding John Neumaier, M.D., Ph.D. Department of Psychiatry Harborview Medical Center and University.
Nora D. Volkow, M.D. Director National Institute on Drug Abuse Nora D. Volkow, M.D. Director National Institute on Drug Abuse What Do We Know? Drug Abuse.
Prevention Research (Children & Adolescents) genetics environment development co-morbidity Prevention Research (Children & Adolescents) genetics environment.
Nora D. Volkow, M.D. Director National Institute on Drug Abuse Nora D. Volkow, M.D. Director National Institute on Drug Abuse RESEARCH and TREATMENT Provide.
1 Impaired Decision Making In Substance Use Disorders Claire Wilcox MD UNM Dept of Psychiatry Alcohol Medical Scholars Program © AMSP.
Methamphetamine and the Brain: A Problem of Inhibitory Control Edythe D. London, Ph.D. David Geffen School of Medicine, UCLA.
Disease X in 1985 No Data
The Neurobiology of Addiction
Bringing the Full Power of Science to Bear on Bringing the Full Power of Science to Bear on NIDA NATIONAL INSTITUTE ON DRUG ABUSE Drug Abuse & Addiction.
 Remember, your brain grows until what age ____???  Also, the amygdala is _______________which makes your brain more sensitive to new, exciting, dangerous.
Recreational Therapy: An Introduction Chapter 5: Substance Use Disorders PowerPoint Slides.
 It is when one is dependent on any kind of substance, illegal drug or a medication  You may not be able to control your drug use  It can cause an.
Director, National Institute on Drug Abuse National Institute Alcohol
THE CORRELATION BETWEEN NEUROSCIENCE AND THE BIOPSYCHOSOCIAL DISEASE OF ADDICTION Presented by Peter Ninemire, LMSW, LCAC Counseling The Caring Center.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
C2004 Alcohol Medical Scholars Program1 Craving Karen Drexler, M.D. Emory University School of Medicine.
Addiction A disease. Facts About Addiction & Treatment WHAT IS ADDICTION? A BRAIN DISEASE BUT WITH BIOLOGICAL, PSYCHOLOGICAL & SOCIAL COMPONENTS DOES.
Chapter 13: Health and Stress. What exactly is Substance Abuse? 1. How would you describe it? In other words, how is abuse different from use? 2. Psychologist.
Mainstreaming Addictions in Medicine: Improving Substance Abuse Services Through Standardization Wilson M. Compton, M.D., M.P.E. Director, Division of.
Substance Use & Abuse Contributing Factors, Physiological & Sociological Effects, Legal Issues.
Multiple Neuronal Systems Thought to be Involved in Nicotine Dependence Frank Vocci, Ph.D. Director Division of Treatment Research and Development National.
 Remember, your brain grows until what age ____???  Also, the amygdala is _______________which makes your brain more sensitive to new, exciting, dangerous.
Addiction Treatment as HIV Prevention Charles P. O’Brien, MD, PhD David Metzger, PhD George E. Woody, MD University of Pennsylvania Treatment Research.
Neurocircuitry of Relapse. Circuitry Mediating Motivated Behavior VTA dopamine Basal Ganglia Anterior Cingulate Ventral Orbital Amygdala Hippocampus Opioids.
Addiction: It’s a Brain Disease Beyond a Reasonable Doubt.
RAMAR  SINCE 1980, RAMAR HAS BEEN A VITAL PART OF RECOVERY FOR CHRONICALLY ADDICTED RECOVERY FOR CHRONICALLY ADDICTED INDIVIDUALS IN NEED IN SUMMIT COUNTY.
Neurological Disorders Lesson 5.2 How do drugs alter synaptic transmission? Human Brain Rat Brain.
Nora D. Volkow, M.D. Director National Institute on Drug Abuse Nora D. Volkow, M.D. Director National Institute on Drug Abuse Research Advances in What.
1 Impaired Decision Making In Substance Use Disorders Claire Wilcox MD UNM Dept of Psychiatry Alcohol Medical Scholars Program © AMSP.
Slide 1: The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health and is dedicated to bringing the power of science to.
Injection Drug Use and Hepatitis C What Can We Do About It? Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse.
DRUG ADDICTION AND ABUSE
The Biology of Addiction By Dr. Springer University of Nebraska-Lincoln.
UNIT 4 BRAIN, BEHAVIOUR & EXPERIENCE AREA OF STUDY 2 MENTAL HEALTH.
The Neurobiology of Free Will In National Institute on Drug Abuse
Common Brain Mechanisms in ADDICTION Common Brain Mechanisms in ADDICTION Nora D. Volkow, M.D. Director National Institute on Drug Abuse Nora D. Volkow,
John Boffa Chief Medical Officer Public Health Assoc Prof., NDRI A Comprehensive primary health care approach to ICE, alcohol and other drugs John Boffa.
NICOTINE and the BRAIN Wilson M. Compton, MD, MPE Deputy Director, U.S. National Institute on Drug Abuse.
Physiology and Behaviour of Withdrawal Syndrome Idrees M, Hussain A, Hyman A, Humphries R & Hughes E. Introduction: Chronic administration of certain drugs.
Principles of Effective Drug Addiction Treatment Health 10 The Truth About Drugs Ms. Meade.
NATIONAL INSTITUTE ON DRUG ABUSE NIDA NIAAA National Institute Alcohol Abuse and Alcoholism Nora D. Volkow, M.D. Director, National Institute on Drug Abuse.
Addressing Adolescent Drug Abuse: Effective Treatment and Principles New Frontiers of Action and New Challenges of Management in Citizen Security San Jose,
Vivitrol (Naltrexone) Treatment for opioid addiction.
First Marijuana Use, (Percent of Initiates) 1.5% 67% 5.5% 25 Addiction is a Developmental Disease: It Starts Early 26%
Today’s class 1. Housekeeping  Moodle  Did you me your statement for HW 1? 2. Lecture – Brain disease or public health challenge? 3. Dr. Volkow’s.
NICOTINE and the BRAIN Wilson M. Compton, MD, MPE Deputy Director, U.S. National Institute on Drug Abuse.
The Science of Addiction. Homelessness Crime Violence Homelessness Crime Violence Neurotoxicity AIDS, Cancer Mental illness Neurotoxicity AIDS, Cancer.
Treating DRUG ADDICTION: What Do We Know? What More Should We Do?
Optimizing Care for PWIDs
Integrating Addiction into Medical Education
National Institute on Drug Abuse
Adolescents and Substance Abuse
Opioids, Pain and Addiction
U.P. Health Strategies May 8, 2018.
Substance abuse reveiw
Impaired Decision Making In Substance Use Disorders
Abnormal Psychology Chapter 9 Substance Use Disorders Second Edition
Motivation and drive in addiction
The reward system in addiction
The Brain on Drugs: From Reward to Addiction
The role of the PFC in addiction
Opioid Use Disorders: Impact on HIV
Presentation transcript:

Nora D. Volkow, M.D. Director National Institute on Drug Abuse National Institutes of Health Nora D. Volkow, M.D. Director National Institute on Drug Abuse National Institutes of Health

Healthy Heart Diseased Heart Decreased Heart Metabolism in Heart Disease Patient ADDICTION IS A DISEASE OF THE BRAIN as other diseases it affects the tissue function Control Cocaine Abuser Decreased Brain Metabolism in Drug Abuse Patient Sources: From the laboratories of Drs. N. Volkow and H. Schelbert High Low

ADDICTION INVOLVES MULTIPLE FACTORS Addiction DRUG Brain Mechanisms Biology/Genes John Smith James Smith Ann Jones John Jones Mary Hill Walter Jones James Hill Susan Adams Alice Price Thomas JonesWilliam Price Richard Hill Steven Adams Allison Fields Mary Walters Alice Benson Rebecca Wilson ThomasSmith John Smith EdwardSmith AnneCook JaneWalker John Walker JaneJones Susan Edwards JamesCook Beth Bryson JonathanCook Edward Bryson Amy Mason Beth Carter Environment

Anatomy DA signal Dopamine Cell DA Transporters DA Receptors Metabolism Brain Dopamine System

Dopamine D2 Receptors are Lower in Addiction DA D2 Receptor Availability Cocaine Alcohol DA Reward Circuits DA Reward Circuits DA Drug Abuser Non-Drug Abuser Heroin Meth control addicted Adapted from Volkow et al., Neurobiology of Learning and Memory 78: , 2002.

2nd D2R Vector Percent Change in D2R p < p < p < 0.10 p < st D2R Vector 0 N ull Vector Time (days) p < % Change in Alcohol Intake p < p < Overexpression of DA D2 receptors reduces alcohol self-administration Overexpression of DA D2 receptors reduces alcohol self-administration Thanos, PK et al., J Neurochem, 78, pp , DA Effects of Tx with an Adenovirus Carrying a DA D2 Receptor Gene into NAc in DA D2 Receptors

Becomes Subordinate Stress remains Individually Housed Group Housed Morgan, D. et al. Nature Neuroscience, 5: , * * S Reinforcers (per session) Cocaine (mg/kg/injection) Dominant Subordinate Becomes Dominant No longer stressed Isolation Can Change Neurobiology Effects of a Social Stressor on Brain DA D2 Receptors and Propensity to Administer Drugs

ADDICTION CONTRIBUTES TO MANY SERIOUS MEDICAL CONSEQUENCES Mental Illness Cancer Infectious Diseases (HIV, HCV) Cardiac Pulmonary Learning Disorders Obesity Cerebrovascular (strokes) Trauma (accidents)

Partial Recovery of Brain Dopamine Transporters in Methamphetamine (METH) Abuser After Protracted Abstinence Normal Control METH Abuser (1 month detox) METH Abuser (14 months detox) 0 3 ml/gm Source: Volkow, ND et al., Journal of Neuroscience 21, , ADDICTION CAN BE TREATED

HIV Seroconversion at 18 Months By Receipt of Treatment Rate of Seroconversion (%) Treatment Status No treatment Partial treatment Continuous treatment Source: Metzger, D. S., Woody, G. E., McLellan, A. T., O’Brien, C. P., Druley, P., Navaline, H., De Philipps, D., Stolley, P., & Abrutyn, E. (1993). Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes, 6, Among IDUs the Most Effective HIV/AIDS Prevention Strategy is Drug Abuse Treatment

Medications for Relapse Prevention Addicted Brain Drive Control Saliency Memory GO Strengthen prefrontal- striatal communication Strengthen prefrontal- striatal communication Executive function/ Inhibitory control Executive function/ Inhibitory control Interfere with conditioned memories (craving) Interfere with conditioned memories (craving) Teach new memories Counteract stress responses that lead to relapse Counteract stress responses that lead to relapse Interfere with drug’s reinforcing effects Interfere with drug’s reinforcing effects Vaccines Enzymatic degredation Naltrexone DA D3 antagonists CB 1 antagonists Vaccines Enzymatic degredation Naltrexone DA D3 antagonists CB 1 antagonists Biofeedback Modafinil Bupropion Stimulants Biofeedback Modafinil Bupropion Stimulants Antiepileptic GVG N-acetylcysteine Antiepileptic GVG N-acetylcysteine Cycloserine CRF antagonists Orexin antagonists CRF antagonists Orexin antagonists STOP Drive Control Memory Non-Addicted Brain Saliency Adenosine A2 antagonists DA D3 antagonists Adenosine A2 antagonists DA D3 antagonists

Drive OFC Drive OFC Saliency NAc Saliency NAc Memory Amygdala Memory Amygdala Control CG Control CG Non-Addicted Brain Addicted Brain STOP GO Drive Memory Saliency Control Drive Memory Saliency Adapted from: Volkow et al., J Clin Invest 111(10): , Adapted from: Volkow et al., J Clin Invest 111(10): , 2003.

Cocaine abusers, when directed, can inhibit cue-induced craving and decrease limbic activity No-Inhibition (NI) NICI Self-report Craving (1-10) *** Before After p u < Cognitive-Inhibition (CI)

ACG OFC SCC Hipp NAcc VP Amyg REWARD INHIBITORY CONTROL INHIBITORY CONTROL MEMORY/ LEARNING MEMORY/ LEARNING EXECUTIVE FUNCTION EXECUTIVE FUNCTION PFC MOTIVATION/ DRIVE MOTIVATION/ DRIVE MULTIPLE BRAIN CIRCUITS ARE INVOLVED IN ADDICTION

Mapping Drug Risk Factors in a Community Poor family support Drug availability Poverty Crime What are the neurobiological factors that mediate social stressors as a risk factor for drug abuse?